Valneva up sharply, contract in sight for its anti-Covid vaccine with Brussels

Valneva has announced that it is in advanced discussions with the European Commission for the supply of a maximum of 60 million doses of its candidate vaccine against Covid-19. (Photo credit: Pixabay – fernando zhiminaicela)

(AOF) – Valneva (+ 16.36% to 9.39 euros), whose title was suspended until 1:30 p.m., announced that it was in advanced discussions with the European Commission for the supply of a maximum of 60 million doses of its candidate vaccine against Covid-19, VLA2001. It entered a Phase 1/2 clinical study in December 2020 and Valneva plans to publish the first safety and immunogenicity data in April 2021.

Based on the analysis of this data, Valneva will select the optimal vaccine dose and initiate the second part of the Phase 1/2 trials. Subject to successful clinical development, Valneva could receive initial marketing authorization in the second half of 2021.

The President of the European Commission, Ursula von der Leyen, spoke about this: “Due to the persistence of the Covid-19 pandemic in Europe and around the world, it is more important than ever that all States members have access to as wide a range of vaccines as possible to help protect populations, in Europe and beyond. Today’s move towards reaching agreement with Valneva further completes the vaccine portfolio Union and demonstrates the Commission’s commitment to finding a lasting solution to the pandemic. “

In September 2020, Valneva announced the signing of a major partnership with the UK government for the supply of up to 190 million doses of its inactivated vaccine candidate, VLA2001. Under the terms of the deal, if the vaccine is successfully developed, Valneva will provide the UK government with 60 million doses in the second half of 2021.

AOF – LEARN MORE

Excellent prospects for the sector

According to Moody’s, the turnover of the sector should increase by 4 to 6% in 2021, against 2 to 4% initially forecast.

The top five vaccine manufacturers (Pfizer-BioNTech, Moderna, AstraZeneca, Novavax and Johnson & Johnson) should benefit greatly from this growth, even if there are uncertainties about production capacities. Treatment manufacturers (Gilead, Eli Lilly and Regeneron in particular) should not be left out.

Alongside the opportunities there are also threats, one of which is potential price reductions, especially in the United States, the world’s largest market. The rise of biosimilars (generics of biological drugs) should also help pull prices down.

.

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.